ClinicalTrials.gg
CompletedNCT01231516SAILINGUpdated Mar 15, 2022Results posted

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

A Phase 3 interventional study of GSK1349572 and Raltegravir in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 181 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-15.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
724
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
7th of 55
724 · median 126
Started
2010
with 3 others
Phase 3
21 of 55
2 open now
Registered
7th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 7th largest by enrollment, is one of 4 that started in 2010, is one of 21 in phase 3, and was the 7th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an investigator selected background regimen consisting of at least one fully active agent plus no more than one second single agent which may or may not be active. Antiviral activity, safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.

Read the detailed description

ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an investigator selected background regimen consisting of at least one fully active agent plus no more than one second single agent which may or may not be active. Antiviral activity, safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.

Subjects must have documented genotypic or phenotypic resistance to at least one member of each of at least two antiretroviral therapy (ART) drug classes [nucleoside/nucleotide reverse transcriptase inhibitor (N[t]RTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), fusion inhibitor (T20), or entry inhibitor (chemokine receptor 5 [CCR5] antagonist)].

The primary analysis will take place after the last subject completes 48 weeks on therapy. An additional data cut and analysis will be conducted after the last subject completes 24 weeks on therapy.

Subjects randomized to GSK1349572 who successfully complete Week 48 will continue to received GSK1349572 until either it is locally available, until they no longer derive clinical benefit, until they meet a protocol-defined reason for discontinuation, or until development of the compound is terminated.

ViiV Healthcare is the sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Browse trials for

Keywords

  • ART-experienced
  • Integrase inhibitor
  • Raltegravir
  • GSK1349572
  • Integrase inhibitor naive
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's enrollment of 724 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Antiretroviral therapy (ART)-experienced, (HIV) -1 infected adults at least 18 years of age.
  • Women capable of becoming pregnant must use appropriate during the study (as defined by the protocol).
  • HIV-1 infection as documented by HIV-1 RNA >400 copies/mL (c/mL) at Screening and with at least one consecutive HIV-1 RNA >400 c/mL within the four months prior to Screening (unless the Screening HIV-1 RNA is > 1000 c/mL where no additional plasma HIV-1 RNA assessment is needed).
  • Have documented resistance (via Screening resistance test) to two or more different classes of antiretroviral agents. For subjects off ART for at least one month, if Screening resistance results provide a fully active agent and do not show two class resistance then historical resistance results from the subject's most recent resistance testing may be used, following consultation with the study virologist and /or medical monitor.
  • Integrase inhibitor (INI)-naïve, defined as no prior exposure to any INI (e.g. RAL, elvitegravir, or GSK1349572).
  • Able to provide written prior to Screening.
  • French subjects: In France, subjects will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion Criteria:

  • Screening resistance test result indicates no fully active antiviral agents are available for design of the background regimen.
  • Subject-virus does not yield results using genotype/phenotype/tropism at Screening (assay data is essential for eligibility determination).
  • Women who are breastfeeding.
  • Any evidence of an active AIDS-defining condition (except cutaneous Kaposi's sarcoma not requiring systemic therapy or CD4+ \<200c/mm3).
  • Subjects with moderate to severe hepatic impairment as defined by classification.
  • Recent history (less than or equal to 3 months) of upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding.
  • Anticipated need for therapy during the study.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class.
  • History of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma; other localized malignancies require agreement between the investigator and study medical monitor for inclusion of the subject.
  • Treatment with an -1 immunotherapeutic vaccine within 90 days prior to Screening.
  • Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any immunomodulator.
  • Treatment with any agent, other than licensed ART, which has documented activity against HIV-1 in vitro within 28 days of first dose of product.
  • Exposure to an experimental drug and/or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the experimental test agent - whichever is longer, prior to the first dose of IP.
  • French subjects recruited at sites in France will be excluded if the subject has participated in any study using an investigational drug and/or vaccine within 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer - prior to screening for the study or the subject plans to participate simultaneously in another clinical study.
  • Any acute or verified Grade 4 laboratory abnormality.
  • (ALT) >5 times the (ULN).
  • ALT greater than or equal to 3xULN and greater than or equal to 1.5xULN (with >35% direct bilirubin).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
724 participants (actual)

Study arms

  • Experimental
    GSK1349572 + Raltegravir Placebo

    Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.

    Drug: GSK1349572 · Drug: Raltegravir Placebo

  • Active comparator
    Raltegravir + GSK1349572 Placebo

    Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.

    Drug: Raltegravir · Drug: GSK1349572 Placebo

Interventions

  • 50mg once daily

  • 400mg twice daily

  • DrugGSK1349572 Placebo

    Inactive placebo tablet once daily

  • DrugRaltegravir Placebo

    Inactive placebo tablet twice daily

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48

    The percentage of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 48 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the randomized phase of the study.

    Time frame: At Week 48

Secondary outcomes

  1. Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Integrase Inhibitor (INI) Resistance at Time of Protocol Defined Virology Failure (PDVF)

    For par. meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure and Baseline were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) virologic non-response: a decrease in plasma HIV-1 RNA of \<1 logarithm to base 10 (log10) copies/mL by Week 16, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/ mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) virologic rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.

    Time frame: Baseline (Day 1) until PDVF (Up to Week 48)

  2. Number of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

    The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 24 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 24 as nonresponders, as well as participants who switched their concomitant ART prior to Week 24 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurement through Week 24 (within window) while the participant was on-treatment. The result below corresponds to the Week 24 interim analysis.

    Time frame: At Week 24

  3. Number of Participants With Plasma HIV-1 RNA <400 c/mL at Week 24 and Week 48

    The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL at the visit of interest was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at the visit of interest as nonresponders, as well as participants who switched their concomitant ART prior to the visit of interest as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurment (within window) for the timepoint of interest while the participant was on-treatment.

    Time frame: At Week 24 and Week 48

  4. Absolute Values of Cluster of Differentiation 4+ (CD4+) Cell Counts at Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144

    Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Median and interquartile range are presented. Baseline was the latest pre-dose assessment value (Day 1).

    Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144

  5. Change From Baseline in CD4+ Cell Counts at Weeks 4, 8, 12,16, 24, 32, 40, 48, 96 and 144

    Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline was the latest pre-dose assessment value (Day 1). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Median and interquartile range is presented.

    Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144

  6. Number of Participants With Post-Baseline HIV-associated Conditions, Excluding Recurrences, and Disease Progressions

    Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of following conditions (CON), without any CON listed in Categories B and C: Asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: Symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C:Clinical CON listed in acquired immunodeficiency syndrome (AIDS) surveillance case definition. Indicators of CDP defined as:CDC CAT A at Baseline (BS) to CDC CAT C event (EV); CDC CAT B at BS to CDC CAT C EV; CDC CAT C at BS to new CDC CAT C EV; or CDC CAT A, B, or C at BS to death.

    Time frame: Up to Week 480

  7. Number of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities

    All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Higher the grade, more severe the symptoms.

    Time frame: From Baseline (Day 1) until Week 48, including participants with post-treatment events occurring after Week 48 for participants not entering the post-Week 48 Open-Label phase of the study

  8. Number of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities

    Blood samples were collected for the analysis of clinical chemistry and hematology parameters: Alanine aminotransferase (ALT), albumin, alkaline phosphate (ALP), aspartate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hypoonatremia, LDL cholesterol, lipase, total bilirubin, triglycerides, hemoglibin, neutrophils, platelets, white blood cells. Any abnormality in clinical chemistry and hematology parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).Higher the grade, more severe the symptoms.

    Time frame: From Week 48 to Week 480

  9. DTG PK Parameters Including Maximum Plasma Drug Concentration (Cmax), Minimal Plasma Drug Concentration (Cmin), and Average Plasma Pre-dose Concentration (C0_avg)

    Cmax, Cmin and C0_avg were assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. Cmax, Cmin and C0_avg were estimated and reported here.

    Time frame: Pre-dose and at 1 to 3 hours or 4 to 12 hours post-dose at Week 4; Pre-dose at Week 24; Pre-dose and 1 to 3 hours or 4 to 12 hours post-dose at Week 48

  10. DTG PK Parameter Including Pre-dose Concentration (C0)

    C0 was assessed by population PK modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. DTG predose concentration (C0) at Week 4, Week 24, and Week 48 was estimated and reported here.

    Time frame: Pre-dose at Weeks 4, 24 and 48

  11. DTG PK Parameters Including Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau Over a Dosing Interval at Steady State (AUC[0-tau])

    AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. AUC was assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48.

    Time frame: Pre-dose and at 1 to 3 hours or 4 to 12 hours post-dose at Week 4; Pre-dose at Week 24; Pre-dose and 1 to 3 hours or 4 to 12 hours post-dose at Week 48

  12. Change From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Utility Score

    The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-3L utility score ranges from -0.594 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 24 and 48

  13. Change From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Thermometer Scores

    The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. EQ-5D-3L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Participants were asked to rate their current health status using the visual analogue scale 'Thermometer'. Score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better heath. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 24 and 48

Other outcomes

  1. Absolute Values of Cluster of Differentiation 8+ (CD8+) Cell Counts at Weeks 4, 8, 12, 16, 24, 32, 40, and 48

    The absolute value data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.

    Time frame: At Weeks 4, 8, 12, 16, 24, 32, 40, and 48

  2. Change From Baseline in CD8+ Cell Counts at Weeks 4, 8, 12, 16, 24, 32, 40, and 48

    Change from Baseline data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.

    Time frame: Baseline (Day 1); Weeks 4, 8, 12, 16, 24, 32, 40, and 48

08

Results

Posted Jan 31, 2014

Participant flow

This study was conducted to demonstrate non-inferior antiviral activity of dolutegravir (DTG) 50 milligram (mg) once daily versus raltegravir (RAL) 400 mg twice daily in participants with human immunodeficiency viruses (HIV)-1. Long-term antiviral activity, tolerability \& safety were also evaluated

Double-blind Phase (Up to Week [Wk] 48)
Participant flow — Double-blind Phase (Up to Week [Wk] 48)
MilestoneDTG 50 mg ODRAL 400 mg BID
Started360364
Itt-e population357362
Modified (m)itt-e population354361
Completed299283
Not completed6181
Withdrew: Adverse event411
Withdrew: Lack of efficacy2042
Withdrew: Protocol violation96
Withdrew: Met protocol-defined stopping criteria53
Withdrew: Lost to follow-up510
Withdrew: Physician decision11
Withdrew: Withdrawal by subject115
Withdrew: Site closed31
Withdrew: Randomized, but did not receive treatment32
Open-label Phase:From Wk 48 up to Wk 480
Participant flow — Open-label Phase:From Wk 48 up to Wk 480
MilestoneDTG 50 mg ODRAL 400 mg BID
Started295126
Completed227109
Not completed6817
Withdrew: Physician decision50
Withdrew: Lack of efficacy2711
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject63
Withdrew: Met protocol-defined stopping criteria20
Withdrew: Adverse event61
Withdrew: Lost to follow-up122

Outcome measures

PrimaryPercentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48

The percentage of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 48 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the randomized phase of the study.

Time frame:
At Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48
Percentage of participantsDTG 50 mg ODRAL 400 mg BID
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 487164
Statistical analysis
  • DTG 50 mg OD vs RAL 400 mg BID · Cochran-Mantel-Haenszel · p = 0.030 (P-value is for test of superiority.) · Difference in percentage: 7.4 · 95% CI 0.7 to 14.2Analysis was adjusted for BL stratification factors: HIV-1 RNA (\<=50000 versus \[vs\]\>50000 c/mL), darunavir-ritonavir use without primary protease inhibitor mutations (yes vs no), and phenotypic susceptibility score (2 vs \<2) to background regimen.
SecondaryNumber of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Integrase Inhibitor (INI) Resistance at Time of Protocol Defined Virology Failure (PDVF)

For par. meeting one of the criteria for PDVF, plasma samples collected at the time point of virologic failure and Baseline were tested to evaluate any potential genotypic and/or phenotypic evolution of resistance. PDVF was defined as (A) virologic non-response: a decrease in plasma HIV-1 RNA of \<1 logarithm to base 10 (log10) copies/mL by Week 16, with subsequent confirmation, unless plasma HIV-1 RNA is \<400 copies/ mL; confirmed plasma HIV-1 RNA levels \>=400 copies/mL on or after Week 24 or (B) virologic rebound: confirmed rebound in plasma HIV-1 RNA levels to \>=400 copies/mL after prior confirmed suppression to \<400 copies/mL; confirmed plasma HIV-1 RNA levels \>1 log10 copies/mL above the nadir value, where nadir is \>=400 copies/mL.Treatment-emergent IN mutations are those detected at the time of PDVF but not at Baseline.

Time frame:
Baseline (Day 1) until PDVF (Up to Week 48)
Reported as:
Count of participants · Participants
Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Integrase Inhibitor (INI) Resistance at Time of Protocol Defined Virology Failure (PDVF)
ParticipantsDTG 50 mg ODRAL 400 mg BID
Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Integrase Inhibitor (INI) Resistance at Time of Protocol Defined Virology Failure (PDVF)417
SecondaryNumber of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<50 c/mL at Week 24 was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at Week 24 as nonresponders, as well as participants who switched their concomitant ART prior to Week 24 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurement through Week 24 (within window) while the participant was on-treatment. The result below corresponds to the Week 24 interim analysis.

Time frame:
At Week 24
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
ParticipantsDTG 50 mg ODRAL 400 mg BID
Number of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24281252
SecondaryNumber of Participants With Plasma HIV-1 RNA <400 c/mL at Week 24 and Week 48

The number of participants with Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL at the visit of interest was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA at the visit of interest as nonresponders, as well as participants who switched their concomitant ART prior to the visit of interest as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA measurment (within window) for the timepoint of interest while the participant was on-treatment.

Time frame:
At Week 24 and Week 48
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 RNA <400 c/mL at Week 24 and Week 48
ParticipantsDTG 50 mg ODRAL 400 mg BID
Week 24307287
Week 48278257
SecondaryAbsolute Values of Cluster of Differentiation 4+ (CD4+) Cell Counts at Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144

Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Median and interquartile range are presented. Baseline was the latest pre-dose assessment value (Day 1).

Time frame:
Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144
Reported as:
Median · Cells per cubic millimeter
Absolute Values of Cluster of Differentiation 4+ (CD4+) Cell Counts at Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144
Cells per cubic millimeterDTG 50 mg ODRAL 400 mg BID
Baseline (Day 1), n=354, 361204.5 (88 to 368)193.0 (96 to 365)
Week 4, n=341, 351266.0 (164 to 416)253.0 (153 to 425)
Week 8, n=338, 346280.0 (179 to 423)268.0 (163 to 445)
Week 12, n=335, 345296.0 (188 to 451)289.0 (174 to 443)
Week 16, n=327, 338299.0 (179 to 462)293.0 (186 to 460)
Week 24, n=326, 326334.5 (201 to 488)326.5 (198 to 473)
Week 32, n=309, 309332.0 (229 to 482)338.0 (215 to 484)
Week 40, n=299, 292376.0 (239 to 523)349.0 (227 to 500)
Week 48, n=298, 286387.0 (247 to 565)378.5 (247 to 521)
Week 96, n=260, 22436.5 (300 to 616)484.5 (393 to 573)
Week 144, n=192, 18500.0 (346 to 657)535.0 (371 to 579)
SecondaryChange From Baseline in CD4+ Cell Counts at Weeks 4, 8, 12,16, 24, 32, 40, 48, 96 and 144

Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline was the latest pre-dose assessment value (Day 1). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Median and interquartile range is presented.

Time frame:
Baseline (Day 1) and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 96 and 144
Reported as:
Median · Cells per cubic millimeter
Change From Baseline in CD4+ Cell Counts at Weeks 4, 8, 12,16, 24, 32, 40, 48, 96 and 144
Cells per cubic millimeterDTG 50 mg ODRAL 400 mg BID
Week 4, n=341, 35153.0 (0 to 109)45.0 (5 to 99)
Week 8, n=338, 34660.5 (15 to 117)59.0 (12 to 124)
Week 12, n=335, 34574.0 (25 to 135)75.0 (22 to 141)
Week 16, n=327, 33876.0 (20 to 156)79.5 (28 to 158)
Week 24, n=326, 32699.0 (34 to 184)93.0 (46 to 166)
Week 32, n=309, 309107.0 (49 to 188)116.0 (52 to 173)
Week 40, n=299, 292125.0 (57 to 212)117.5 (51.5 to 192)
Week 48, n=298, 286144.0 (73 to 239)137.0 (65 to 222)
Week 96, n=260, 22198.5 (92.5 to 299.5)270 (209 to 348)
Week 144, n= 192, 18243.0 (138 to 357)302.5 (154 to 390)
SecondaryNumber of Participants With Post-Baseline HIV-associated Conditions, Excluding Recurrences, and Disease Progressions

Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of following conditions (CON), without any CON listed in Categories B and C: Asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: Symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C:Clinical CON listed in acquired immunodeficiency syndrome (AIDS) surveillance case definition. Indicators of CDP defined as:CDC CAT A at Baseline (BS) to CDC CAT C event (EV); CDC CAT B at BS to CDC CAT C EV; CDC CAT C at BS to new CDC CAT C EV; or CDC CAT A, B, or C at BS to death.

Time frame:
Up to Week 480
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline HIV-associated Conditions, Excluding Recurrences, and Disease Progressions
ParticipantsDTG 50 mg ODRAL 400 mg BID
Any CAT3225
CAT B1614
CAT C128
Death64
Progression from CAT A to CAT C21
Progression from CAT B to CAT C01
Progression from CAT C to New CAT C95
Progression from CAT A, B, or C to Death64
SecondaryNumber of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities

All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Higher the grade, more severe the symptoms.

Time frame:
From Baseline (Day 1) until Week 48, including participants with post-treatment events occurring after Week 48 for participants not entering the post-Week 48 Open-Label phase of the study
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities
ParticipantsDTG 50 mg ODRAL 400 mg BID
ALT4746
Albumin43
ALP2742
AST4952
CO2 content/bicarbonate97109
Cholesterol99103
CK2829
Creatinine1813
Hyperglycaemia7180
Hyperkalemia76
Hypernatremia57
Hypoglycaemia2114
Hypokalemia3741
Hyponatremia7679
LDL cholesterol calculation6882
Lipase6368
Total bilirubin5653
Triglycerides1424
Hemoglobin1927
Platelet count3632
Total neutrophils4949
White Blood Cell count1929
SecondaryNumber of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities

Blood samples were collected for the analysis of clinical chemistry and hematology parameters: Alanine aminotransferase (ALT), albumin, alkaline phosphate (ALP), aspartate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hypoonatremia, LDL cholesterol, lipase, total bilirubin, triglycerides, hemoglibin, neutrophils, platelets, white blood cells. Any abnormality in clinical chemistry and hematology parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening).Higher the grade, more severe the symptoms.

Time frame:
From Week 48 to Week 480
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities
ParticipantsDTG 50 mg ODRAL 400 mg BID
ALT, Grades 1 to 4369
ALT, Grades 2 to 4113
ALT, Grades 3 to 440
Albumin, Grades 1 to 430
Albumin, Grades 2 to 430
Albumin, Grades 3 to 400
ALP, Grades 1 to 4201
ALP, Grades 2 to 441
ALP, Grades 3 to 411
AST, Grades 1 to 4368
AST, Grades 2 to 4140
AST, Grades 3 to 410
CO2 content/bicarbonate, Grades 1 to 410021
CO2 content/bicarbonate, Grades 2 to 4123
CO2 content/bicarbonate, Grades 3 to 400
Cholesterol, Grades 1 to 413826
Cholesterol, Grades 2 to 46616
Cholesterol, Grades 3 to 4113
CK, Grades 1 to 4354
CK, Grades 2 to 4111
CK, Grades 3 to 421
Creatinine, Grades 1 to 4202
Creatinine, Grades 2 to 482
Creatinine, Grades 3 to 421
Hyperglycemia, Grades 1 to 49410
Hyperglycemia, Grades 2 to 4406
Hyperglycemia, Grades 3 to 471
Hyperkalemia, Grades 1 to 491
Hyperkalemia, Grades 2 to 441
Hyperkalemia, Grades 3 to 420
Hypernatremia, Grades 1 to 471
Hypernatremia, Grades 2 to 410
Hypernatremia, Grades 3 to 400
Hypoglycemia, Grades 1 to 4224
Hypoglycemia, Grades 2 to 421
Hypoglycemia, Grades 3 to 400
Hypokalemia, Grades 1 to 42913
Hypokalemia, Grades 2 to 411
Hypokalemia, Grades 3 to 400
Hyponatremia, Grades 1 to 45515
Hyponatremia, Grades 2 to 420
Hyponatremia, Grades 3 to 400
LDL cholesterol, Grades 1 to 410722
LDL cholesterol, Grades 2 to 44610
LDL cholesterol, Grades 3 to 4153
Lipase, Grades 1 to 4677
Lipase, Grades 2 to 4353
Lipase, Grades 3 to 4120
Total bilirubin, Grades 1 to 45211
Total bilirubin, Grades 2 to 44210
Total bilirubin, Grades 3 to 4186
Triglycerides, Grades 1 to 4232
Triglycerides, Grades 2 to 4232
Triglycerides, Grades 3 to 4111
Hemoglobin, Grades 1 to 4116
Hemoglobin, Grades 2 to 460
Hemoglobin, Grades 3 to 420
Neutrophils, Grades 1 to 4379
Neutrophils, Grades 2 to 4144
Neutrophils, Grades 3 to 472
Platelets, Grades 1 to 4227
Platelets, Grades 2 to 4111
Platelets, Grades 3 to 440
White Blood Cells, Grades 1 to 4173
White Blood Cells, Grades 2 to 471
White Blood Cells, Grades 3 to 400
SecondaryDTG PK Parameters Including Maximum Plasma Drug Concentration (Cmax), Minimal Plasma Drug Concentration (Cmin), and Average Plasma Pre-dose Concentration (C0_avg)

Cmax, Cmin and C0_avg were assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. Cmax, Cmin and C0_avg were estimated and reported here.

Time frame:
Pre-dose and at 1 to 3 hours or 4 to 12 hours post-dose at Week 4; Pre-dose at Week 24; Pre-dose and 1 to 3 hours or 4 to 12 hours post-dose at Week 48
Reported as:
Geometric mean · microgram/milliliter (µg/mL)
DTG PK Parameters Including Maximum Plasma Drug Concentration (Cmax), Minimal Plasma Drug Concentration (Cmin), and Average Plasma Pre-dose Concentration (C0_avg)
microgram/milliliter (µg/mL)DTG 50 mg OD
C0_avg, n=3420.926 ± 131
Cmax, n=3403.21 ± 26.7
Cmin, n=3400.849 ± 76.5
SecondaryDTG PK Parameter Including Pre-dose Concentration (C0)

C0 was assessed by population PK modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48. DTG predose concentration (C0) at Week 4, Week 24, and Week 48 was estimated and reported here.

Time frame:
Pre-dose at Weeks 4, 24 and 48
Reported as:
Geometric mean · microgram/milliliter (µg/mL)
DTG PK Parameter Including Pre-dose Concentration (C0)
microgram/milliliter (µg/mL)DTG 50 mg OD
Week 4, n=3290.786 ± 143
Week 24, n=2980.940 ± 132
Week 48, n=2760.932 ± 152
SecondaryDTG PK Parameters Including Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau Over a Dosing Interval at Steady State (AUC[0-tau])

AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. AUC was assessed by population pharmacokinetic (PK) modeling using sparse PK samples which were collected as follows: one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 4, one pre-dose sample at Week 24, and one pre-dose sample and one post-dose sample at 1 to 3 hours/4 to 12 hours at Week 48.

Time frame:
Pre-dose and at 1 to 3 hours or 4 to 12 hours post-dose at Week 4; Pre-dose at Week 24; Pre-dose and 1 to 3 hours or 4 to 12 hours post-dose at Week 48
Reported as:
Geometric mean · Micrograms*hour/milliliter (µg*hr/mL)
DTG PK Parameters Including Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau Over a Dosing Interval at Steady State (AUC[0-tau])
Micrograms*hour/milliliter (µg*hr/mL)DTG 50 mg OD
DTG PK Parameters Including Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau Over a Dosing Interval at Steady State (AUC[0-tau])44.7 ± 40.5
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Utility Score

The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-3L utility score ranges from -0.594 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Utility Score
Scores on a scaleDTG 50 mg ODRAL 400 mg BID
Week 24, n=350, 3560.010 ± 0.2020.019 ± 0.204
Week 48, n=350, 3560.028 ± 0.1790.013 ± 0.222
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Thermometer Scores

The EQ-5D-3L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 3 levels for each dimension including 1=no problems, 2=some problems, 3=extreme problems. EQ-5D-3L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Participants were asked to rate their current health status using the visual analogue scale 'Thermometer'. Score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better heath. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L) Thermometer Scores
Scores on a scaleDTG 50 mg ODRAL 400 mg BID
Week 24, n=350, 3556.800 ± 21.4134.645 ± 18.279
Week 48, n=350, 3558.894 ± 20.3565.597 ± 18.821
Other pre-specifiedAbsolute Values of Cluster of Differentiation 8+ (CD8+) Cell Counts at Weeks 4, 8, 12, 16, 24, 32, 40, and 48

The absolute value data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.

Time frame:
At Weeks 4, 8, 12, 16, 24, 32, 40, and 48

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in CD8+ Cell Counts at Weeks 4, 8, 12, 16, 24, 32, 40, and 48

Change from Baseline data for CD8+ cell count was planned to be evaluated. The results for this outcome measure will never be posted.

Time frame:
Baseline (Day 1); Weeks 4, 8, 12, 16, 24, 32, 40, and 48

No measurements were reported for this outcome.

Adverse events

Collected over Serious adverse events (SAEs), non-serious AEs and all-cause mortality were collected from the start of study medication to the end of the study (up to Week 480). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG~50mg QD6/357 (1.7%)73/357 (20.4%)250/357 (70%)
RAL~400mg BID4/362 (1.1%)46/362 (12.7%)206/362 (56.9%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventDTG~50mg QDRAL~400mg BID
PneumoniaInfections and infestations7/3577/362
Suicidal ideationPsychiatric disorders4/3571/362
Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/3570/362
Acute kidney injuryRenal and urinary disorders3/3571/362
Alcohol withdrawal syndromePsychiatric disorders2/3570/362
DepressionPsychiatric disorders2/3570/362
RhabdomyolysisMusculoskeletal and connective tissue disorders2/3570/362
Suicide attemptPsychiatric disorders2/3570/362
Angina pectorisCardiac disorders2/3570/362
Lower respiratory tract infectionInfections and infestations2/3570/362
Most frequent other events
Showing 10 of 22
Most frequent other events
EventDTG~50mg QDRAL~400mg BID
DiarrhoeaGastrointestinal disorders92/35764/362
Upper respiratory tract infectionInfections and infestations72/35737/362
CoughRespiratory, thoracic and mediastinal disorders46/35726/362
HeadacheNervous system disorders43/35736/362
NasopharyngitisInfections and infestations43/35722/362
InfluenzaInfections and infestations42/35734/362
HypertensionVascular disorders39/35715/362
NauseaGastrointestinal disorders35/35731/362
Urinary tract infectionInfections and infestations35/35720/362
ArthralgiaMusculoskeletal and connective tissue disorders34/35727/362

Baseline characteristics

Four participants from one closed site were removed from the ITT-E Population creating the modified ITT-E Population with 715 participants.

Age, Continuous
Age, Continuous(Years)DTG 50 mg ODRAL 400 mg BIDTotal
Mean42.6 ± 10.4542.5 ± 9.8142.5 ± 10.13
Sex: Female, Male
Sex: Female, Male(Participants)DTG 50 mg ODRAL 400 mg BIDTotal
Female107123230
Male247238485
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG 50 mg ODRAL 400 mg BIDTotal
African American/African Heritage143160303
American Indian or Alaska Native101727
Asian-Central/South Asian Heritage224
Asian-East Asian Heritage6410
Asian-South East Asian Heritage101
Native Hawaiian or Other Pacific Islander101
White-Arabic/North African Heritage336
White-White/Caucasian/European Heritage175172347
Mixed Race12214
Unknown112
09

Study locations

181 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Phoenix, Arizona 85012, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72207, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Oakland, California 94609, United States
  • GSK Investigational Site
    New Haven, Connecticut 06520, United States
  • GSK Investigational Site
    Norwalk, Connecticut 06850, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Daytona Beach, Florida 32117, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33401, United States
  • GSK Investigational Site
    Wilton Manors, Florida 33305, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Maywood, Illinois 60153, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01105, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Lansing, Michigan 48911, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    Kansas City, Missouri 64106, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63108, United States
  • GSK Investigational Site
    Omaha, Nebraska 68106, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Neptune, New Jersey 07753, United States
  • GSK Investigational Site
    Newark, New Jersey 07102, United States
  • GSK Investigational Site
    Newark, New Jersey 07103, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    New York, New York 10003, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    Valhalla, New York 10595, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Akron, Ohio 44304, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Allentown, Pennsylvania 18102, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
  • GSK Investigational Site
    Dallas, Texas 75204, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Houston, Texas 77401, United States
  • GSK Investigational Site
    Longview, Texas 75605, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84132, United States
  • GSK Investigational Site
    Annandale, Virginia 22003, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1264AAJ, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1405CKC, Argentina
  • GSK Investigational Site
    Ciudad de Buenos Aires, Buenos Aires C1202ABB, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe 2000, Argentina
  • GSK Investigational Site
    Buenos Aires, 1141, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, C1181ACH, Argentina
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
  • GSK Investigational Site
    Antwerpen, 2000, Belgium
  • GSK Investigational Site
    Brussels, 1000, Belgium
  • GSK Investigational Site
    Charleroi, 6000, Belgium
  • GSK Investigational Site
    Liege, 4000, Belgium
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30130100, Brazil
  • GSK Investigational Site
    Curitiba, Paraná 80240-280, Brazil
  • GSK Investigational Site
    Sao Paulo, São Paulo 01246-090, Brazil
  • GSK Investigational Site
    Sao Paulo, São Paulo 04040-002, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21040-360, Brazil
  • GSK Investigational Site
    Salvador, 40110-060, Brazil
  • GSK Investigational Site
    Santos, 11045-904, Brazil
  • GSK Investigational Site
    São Paulo, 04121-000, Brazil
  • GSK Investigational Site
    Vitoria, 29041-091, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N3Z5, Canada
  • GSK Investigational Site
    Toronto, Ontario M4T 3A7, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 5B1, Canada
  • GSK Investigational Site
    Montreal, Quebec H2W 1T8, Canada
  • GSK Investigational Site
    Puente Alto - Santiago, Región Metro De Santiago 8207257, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8320000, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8330074, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8900088, Chile
  • GSK Investigational Site
    Santiago, 8360159, Chile

Showing the first 100 of 181 sites across 20 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum In: Lancet. 2014 Jan 4;383(9911):30. PubMed 23830355 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2010 to primary completion in Feb 2013, 27 months.

Results were first posted in Jan 2014, 11 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 27 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2010
First posted
Nov 1, 2010
StartActual
Oct 26, 2010
Primary completionActual
Feb 4, 2013
CompletionActual
Feb 2, 2021
Results first posted
Jan 31, 2014
Last update
Mar 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01231516
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Nov 1, 2010
Start date
Oct 26, 2010
Primary completion
Feb 4, 2013
Completion
Feb 2, 2021
Results posted
Jan 31, 2014
Last update
Mar 15, 2022

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion